Follow the people · Insider
Apeiron Investment Group Ltd.
Apeiron Investment Group Ltd. files insider transactions with the SEC as a director and 10% owner of Enhanced Group (ENHA). We hold 6 disclosed purchases and sales filed since 12 April 2022, 6 of them in the last 90 days.
- Files forENHA
- Disclosed buys and sells6 in all, 6 in the last 90 days
- Last disclosure4 September 2026
Positions held
5 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 7 May 2026 — 3 September 2026Director and 10% owner · Enhanced Group (ENHA)14 Form 4 lines · source: SEC Form 4
- Filed 8 April 2022 — 30 September 202510% owner · ATAI Life Sciences (ATAI)12 Form 4 lines · source: SEC Form 4
- Filed 2 October 2024 — 4 October 202410% owner · Bionomics Ltd/adr (BNOX)3 Form 4 lines · source: SEC Form 4
- Filed 6 February 2024 — 6 February 2024Other role · Alto Neuroscience (ANRO)6 Form 4 lines · source: SEC Form 4
- Filed 23 February 2023 — 23 February 202310% owner · Sensei Biotherapeutics (SNSE)2 Form 4 lines · source: SEC Form 4
Everything they disclosed
37 entries, newest first — one per disclosure report, one per Form 4 line- ▲ bought on the open market 107,693 shares of Enhanced GroupSEC Form 44 September 2026Class A Common Stock · traded 2 September 2026 · filed 4 September 2026
- ▲ bought on the open market 25,414 shares of Enhanced GroupSEC Form 44 September 2026Class A Common Stock · traded 3 September 2026 · filed 4 September 2026
- was granted 2,120,823 shares of Enhanced GroupSEC Form 420 August 2026Class A Common Stock · traded 14 August 2026 · filed 20 August 2026
- ▲ bought on the open market 93,000 shares of Enhanced GroupSEC Form 420 August 2026Class A Common Stock · traded 18 August 2026 · filed 20 August 2026
- ▲ bought on the open market 1,619,316 shares of Enhanced GroupSEC Form 420 August 2026Class A Common Stock · traded 19 August 2026 · filed 20 August 2026
- ▲ bought on the open market 55,000 shares of Enhanced GroupSEC Form 420 August 2026Class A Common Stock · traded 19 August 2026 · filed 20 August 2026
- was granted 2,120,823 shares of Enhanced Group (a derivative holding)SEC Form 420 August 2026Warrants · traded 14 August 2026 · filed 20 August 2026
- ▲ bought on the open market 200,000 shares of Enhanced GroupSEC Form 418 August 2026Class A Common Stock · traded 17 August 2026 · filed 18 August 2026
- ▲ bought on the open market 150,000 shares of Enhanced GroupSEC Form 417 August 2026Class A Common Stock · traded 14 August 2026 · filed 17 August 2026
- was granted 3,020,565 shares of Enhanced GroupSEC Form 424 July 2026Class A Common Stock · traded 22 July 2026 · filed 24 July 2026
- was granted 3,020,565 shares of Enhanced Group (a derivative holding)SEC Form 424 July 2026Warrants · traded 22 July 2026 · filed 24 July 2026
- was granted 29,692,247 shares of Enhanced GroupSEC Form 411 May 2026Class A Common Stock · traded 7 May 2026 · filed 11 May 2026
- was granted 258,837,933 shares of Enhanced GroupSEC Form 411 May 2026Class B Common Stock · traded 7 May 2026 · filed 11 May 2026
- was granted 212,499 shares of Enhanced Group (a derivative holding)SEC Form 411 May 2026Warrants · traded 7 May 2026 · filed 11 May 2026
- converted 147,950 shares of ATAI Life Sciences (a derivative holding)SEC Form 42 October 2025Convertible Notes · traded 30 September 2025 · filed 2 October 2025
- converted 2,367,200 shares of ATAI Life SciencesSEC Form 42 October 2025Common Shares · traded 30 September 2025 · filed 2 October 2025
- ▲ bought on the open market 8,675,799 shares of ATAI Life SciencesSEC Form 418 August 2025Common Shares · traded 14 August 2025 · filed 18 August 2025
- ▲ bought on the open market 1,800,000 shares of ATAI Life SciencesSEC Form 424 March 2025Common Shares · traded 24 March 2025 · filed 24 March 2025
- ▲ bought on the open market 10,835,718 shares of ATAI Life SciencesSEC Form 419 February 2025Common Shares · traded 14 February 2025 · filed 19 February 2025
- ▼ sold on the open market 90,806 shares of Bionomics Ltd/adrSEC Form 47 October 2024Ordinary Shares · traded 2 October 2024 · filed 7 October 2024
- ▼ sold on the open market 180,707 shares of Bionomics Ltd/adrSEC Form 47 October 2024Ordinary Shares · traded 3 October 2024 · filed 7 October 2024
- ▼ sold on the open market 557 shares of Bionomics Ltd/adrSEC Form 47 October 2024Ordinary Shares · traded 4 October 2024 · filed 7 October 2024
- converted 444,561 shares of Alto Neuroscience (a derivative holding)SEC Form 46 March 2024Warrants to Purchase Series A Preferred Stock · traded 6 February 2024 · filed 6 March 2024
- converted 406,072 shares of Alto Neuroscience (a derivative holding)SEC Form 46 March 2024Series A Preferred Stock · traded 6 February 2024 · filed 6 March 2024
- converted 1,063,918 shares of Alto Neuroscience (a derivative holding)SEC Form 46 March 2024Series A Preferred Stock · traded 6 February 2024 · filed 6 March 2024
- converted 416,665 shares of Alto Neuroscience (a derivative holding)SEC Form 46 March 2024Series B Preferred Stock · traded 6 February 2024 · filed 6 March 2024
- converted 251,881 shares of Alto NeuroscienceSEC Form 46 March 2024Common Stock · traded 6 February 2024 · filed 6 March 2024
- converted 674,658 shares of Alto NeuroscienceSEC Form 46 March 2024Common Stock · traded 6 February 2024 · filed 6 March 2024
- ▲ bought on the open market 1,100 shares of Sensei BiotherapeuticsSEC Form 427 February 2023Common Stock · traded 23 February 2023 · filed 27 February 2023
- ▲ bought on the open market 1,100 shares of Sensei BiotherapeuticsSEC Form 427 February 2023Common Stock · traded 23 February 2023 · filed 27 February 2023
- ▲ bought on the open market 67,703 shares of ATAI Life SciencesSEC Form 43 May 2022Common Shares · traded 20 April 2022 · filed 3 May 2022
- ▲ bought on the open market 68,688 shares of ATAI Life SciencesSEC Form 43 May 2022Common Shares · traded 21 April 2022 · filed 3 May 2022
- ▲ bought on the open market 54,322 shares of ATAI Life SciencesSEC Form 420 April 2022Common Shares · traded 18 April 2022 · filed 20 April 2022
- ▲ bought on the open market 65,315 shares of ATAI Life SciencesSEC Form 420 April 2022Common Shares · traded 19 April 2022 · filed 20 April 2022
- ▲ bought on the open market 4,967 shares of ATAI Life SciencesSEC Form 418 April 2022Common Shares · traded 14 April 2022 · filed 18 April 2022
- ▲ bought on the open market 57,689 shares of ATAI Life SciencesSEC Form 412 April 2022Common Shares · traded 8 April 2022 · filed 12 April 2022
- ▲ bought on the open market 53,926 shares of ATAI Life SciencesSEC Form 412 April 2022Common Shares · traded 11 April 2022 · filed 12 April 2022
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.